Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02097953 · ClinicalTrials.gov registry record · Early Phase 1
Influence of Rifampin Co-Administration on the Pharmacokinetic Profile of Daptomycin
A Early Phase 1 study, sponsored by University of Utah.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 12
- Enrollment target
NCT02097953 is a Early Phase 1 study that has completed, run by University of Utah. The registered enrollment target is 12 participants.
The verdict
NCT02097953, a Early Phase 1 study, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to understand how an antibiotic, rifampin, may change the blood levels of another antibiotic, daptomycin, in the body. In addition, the effect of polymorphisms in P-glycoprotein (a protein involved in the removal of daptomycin from the body) on the blood levels of daptomycin will be evaluated. The hypotheses are that rifampin will decrease the blood levels of daptomycin and that the effect will be greater for certain P-glycoprotein polymorphisms.
Interventions
- DRUG Rifampin
- DRUG Daptomycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2014-05 |
| Est. Completion | 2016-07 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02097953
The ClinicalTrials.gov registry entry for NCT02097953 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rifampin is the first listed.
NCT02097953 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02097953 about?
NCT02097953 is a clinical study titled "Influence of Rifampin Co-Administration on the Pharmacokinetic Profile of Daptomycin". The purpose of this study is to understand how an antibiotic, rifampin, may change the blood levels of another antibiotic, daptomycin, in the body. In addition, the effect of polymorphisms in P-glycoprotein (a protein involved in the removal of daptomycin from the body) on the blood levels of daptom...
What is the current status of trial NCT02097953?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 12 participants. The study started on 2014-05. Estimated completion is 2016-07.
What interventions are being tested in trial NCT02097953?
The interventions under investigation include: Rifampin (DRUG), Daptomycin (DRUG).
Who is sponsoring clinical trial NCT02097953?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.